Daniele Bergamaschi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Daniele Bergamaschi has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- Catherine A. Harwood
Barts Health NHS Trust and Queen Mary University of London, London, UK
9 shared publications - Giovanna Chiorino
Cancer Genomics Laboratory Fondazione Edo ed Elvo Tempia Biella Italy
8 shared publications Xin Lu
Tumour Cell Death Laboratory, Beatson Institute for Cancer Research, Glasgow, United Kingdom. 2Centre for Oncology and Applied Pharmacology, University of Glasgow, Glasgow, United Kingdom. 3Ludwig Institute for Cancer Research, University College London, London, United Kingdom. 4Tumour Suppression Laboratory, Beatson Institute for Cancer Research, Glasgow, United Kingdom
7 shared publications- Anissa Chikh
Molecular and Clinical Sciences Research Institute, St. George's, University of London, London SW17 0RE, U.K.
5 shared publications Giuseppe Trigiante
Ludwig Institute for Cancer Research, Imperial College School of Medicine, Norfolk Place, London W2 1PG, UK
5 shared publicationsS Ronzoni
Department of Oncology, Istituto di Ricerche Farmacologiche ‘Mario Negri’ Via Eritrea 62, 20157 Milan, Italy
5 shared publications
Latest Publications
- Open Access
- 17 May 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (12) , 2730-2741
Biomechanical Activation of Keloid Fibroblasts Promotes Lysosomal Remodeling and Exocytosis
- 17 May 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (12) , 2730-2741
Open AccessBiomechanical Activation of Keloid Fibroblasts Promotes Lysosomal Remodeling and Exocytosis
- 1 April 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (5) , 929-930
Autophagy Modulation in Endothelial Hyperglycemia-Induced Wound-Healing Impairment
- 1 April 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (5) , 929-930
Autophagy Modulation in Endothelial Hyperglycemia-Induced Wound-Healing Impairment
- 29 January 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (5) , 615-616
Improving cancer stem cells killing in malignant melanoma
Daniele Bergamaschi; Improving cancer stem cells killing in malignant melanoma, British Journal of Dermatology, , ljae035, https://doi.org/10.1093/bjd/ljae035
- 29 January 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (5) , 615-616
Improving cancer stem cells killing in malignant melanoma
Daniele Bergamaschi; Improving cancer stem cells killing in malignant melanoma, British Journal of Dermatology, , ljae035, https://doi.org/10.1093/bjd/ljae035
- Open Access
A biomechanical switch promotes lysosomal remodelling and exocytosis in keloid fibroblasts
Keloids are a severe form of scarring for which the underlying mechanisms are poorly understood, and treatment options are limited or inconsistent. While biomechanical forces are potential drivers of keloid scarring, the direct cellular responses to mechanical cues have yet to be defined. The aim of this study was to examine the distinct responses of normal dermal fibroblasts (NDFs) and keloid-derived fibroblasts (KDFs) to changes in extracellular matrix (ECM) stiffness. When cultured on hydrogels mimicking the elasticity of normal or scarred skin, KDFs displayed greater stiffness-dependent increases in cell spreading, F-actin stress fibre formation, and focal adhesion assembly. Elevated acto-myosin contractility in KDFs disrupted the normal mechanical regulation of ECM remodelling, leading to constitutive collagen and fibronectin deposition. Transcriptional profiling identified mechanically-regulated pathways in NDFs and KDFs, including the actin cytoskeleton, Hippo signalling, and autophagy. Further analysis of the autophagy pathway revealed that autophagic flux was intact in both fibroblast populations and depended on acto-myosin contractility. However, KDFs displayed marked changes in lysosome organisation and an increase in lysosomal exocytosis, which was mediated by acto-myosin contractility. Together, these findings demonstrate that KDFs possess an intrinsic increase in cytoskeletal tension, which heightens the response to ECM mechanics and promotes lysosomal exocytosis.
Open AccessA biomechanical switch promotes lysosomal remodelling and exocytosis in keloid fibroblasts
Keloids are a severe form of scarring for which the underlying mechanisms are poorly understood, and treatment options are limited or inconsistent. While biomechanical forces are potential drivers of keloid scarring, the direct cellular responses to mechanical cues have yet to be defined. The aim of this study was to examine the distinct responses of normal dermal fibroblasts (NDFs) and keloid-derived fibroblasts (KDFs) to changes in extracellular matrix (ECM) stiffness. When cultured on hydrogels mimicking the elasticity of normal or scarred skin, KDFs displayed greater stiffness-dependent increases in cell spreading, F-actin stress fibre formation, and focal adhesion assembly. Elevated acto-myosin contractility in KDFs disrupted the normal mechanical regulation of ECM remodelling, leading to constitutive collagen and fibronectin deposition. Transcriptional profiling identified mechanically-regulated pathways in NDFs and KDFs, including the actin cytoskeleton, Hippo signalling, and autophagy. Further analysis of the autophagy pathway revealed that autophagic flux was intact in both fibroblast populations and depended on acto-myosin contractility. However, KDFs displayed marked changes in lysosome organisation and an increase in lysosomal exocytosis, which was mediated by acto-myosin contractility. Together, these findings demonstrate that KDFs possess an intrinsic increase in cytoskeletal tension, which heightens the response to ECM mechanics and promotes lysosomal exocytosis.
- 27 September 2022
- Published by Morressier GmbH
ESDR597 - Altered mechano-sensing and autophagy in keloid dermal fibroblasts
Keloid scars, which are excessive forms of cutaneous scarring, overgrow the boundaries of the original wound and do not regress spontaneously. Al | POSTER
- 27 September 2022
- Published by Morressier GmbH
ESDR597 - Altered mechano-sensing and autophagy in keloid dermal fibroblasts
Keloid scars, which are excessive forms of cutaneous scarring, overgrow the boundaries of the original wound and do not regress spontaneously. Al | POSTER
- 27 September 2022
- Published by Morressier GmbH
ESDR347 - Chronic Inflammation of Keratinocytes Leads to Autophagy Impairment in Psoriasis
Psoriasis is an inflammatory disorder which leads to the improper stratification of epidermal keratinocytes. Autophagic flux analysis of our esta | POSTER
- 27 September 2022
- Published by Morressier GmbH
ESDR347 - Chronic Inflammation of Keratinocytes Leads to Autophagy Impairment in Psoriasis
Psoriasis is an inflammatory disorder which leads to the improper stratification of epidermal keratinocytes. Autophagic flux analysis of our esta | POSTER
- 15 November 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 186 (2) , 211-212
Autophagy protects from photoageing in skin fibroblasts
- 15 November 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 186 (2) , 211-212
Autophagy protects from photoageing in skin fibroblasts
- 8 July 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 186 (1) , 117-128
GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma
Background Gap junctional intercellular communication is crucial for epidermal cellular homeostasis. Inability to establish melanocyte-keratinocytes contacts and loss of intercellular junction’s integrity may contribute to melanoma development. Connexins, laminins and desmocollins have been implicated in the control of melanoma growth, where their reduced expression has been reported in metastatic lesions. Objectives The aim of this study was to investigate Connexin 31.1 (GJB5) expression and identify any association with BRAF mutational status, melanoma patient prognosis and MAPK inhibitors (MAPKi) treatment. Material and methods GJB5 expression was measured at RNA and protein level in melanoma clinical samples and established cell lines treated or not with BRAF and MEK inhibitors, as well as in cell lines which developed MAPK inhibitors resistance. Findings were further validated and confirmed by analysis of independent datasets. Results Our analysis reveals significant downregulation of GJB5 expression in metastatic melanoma lesions compared to primary ones and in BRAF mutated versus BRAF wild-type melanomas. Likewise, GJB5 expression is significantly lower in BRAFV600E compared with BRAFWT cell lines and increases upon MAPKi treatment. MAPKi-resistant melanoma cells display a similar expression pattern compared to BRAFWT cells, with increased GJB5 expression associated with morphological changes. Enhancement of BRAFV600E expression in BRAFWT melanoma cells significantly upregulates miR-335-5p expression with consequent downregulation of GJB5, one of its targets. Furthermore, overexpression of miR-335-5p in two BRAFWT cell lines confirms specific GJB5 protein downregulation. RT-qPCR analysis also revealed upregulation of miR-335 in BRAFV600E melanoma cells, which is significantly downregulated in cells resistant to MEK inhibitors. Our data were further validated using the TCGA-SKCM dataset, where BRAF mutations associate with increased miR-335 expression and inversely correlate with GJB5 expression. In clinical samples, GJB5 underexpression is also associated with patient overall worse survival, especially at early stages. Conclusion We identified a significant association between metastases / BRAF mutation and low GJB5 expression in melanoma. Our results identify a novel mechanism of Gap-junctional protein regulation, suggesting a prognostic role for GJB5 in cutaneous melanoma.
- 8 July 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 186 (1) , 117-128
GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma
Background Gap junctional intercellular communication is crucial for epidermal cellular homeostasis. Inability to establish melanocyte-keratinocytes contacts and loss of intercellular junction’s integrity may contribute to melanoma development. Connexins, laminins and desmocollins have been implicated in the control of melanoma growth, where their reduced expression has been reported in metastatic lesions. Objectives The aim of this study was to investigate Connexin 31.1 (GJB5) expression and identify any association with BRAF mutational status, melanoma patient prognosis and MAPK inhibitors (MAPKi) treatment. Material and methods GJB5 expression was measured at RNA and protein level in melanoma clinical samples and established cell lines treated or not with BRAF and MEK inhibitors, as well as in cell lines which developed MAPK inhibitors resistance. Findings were further validated and confirmed by analysis of independent datasets. Results Our analysis reveals significant downregulation of GJB5 expression in metastatic melanoma lesions compared to primary ones and in BRAF mutated versus BRAF wild-type melanomas. Likewise, GJB5 expression is significantly lower in BRAFV600E compared with BRAFWT cell lines and increases upon MAPKi treatment. MAPKi-resistant melanoma cells display a similar expression pattern compared to BRAFWT cells, with increased GJB5 expression associated with morphological changes. Enhancement of BRAFV600E expression in BRAFWT melanoma cells significantly upregulates miR-335-5p expression with consequent downregulation of GJB5, one of its targets. Furthermore, overexpression of miR-335-5p in two BRAFWT cell lines confirms specific GJB5 protein downregulation. RT-qPCR analysis also revealed upregulation of miR-335 in BRAFV600E melanoma cells, which is significantly downregulated in cells resistant to MEK inhibitors. Our data were further validated using the TCGA-SKCM dataset, where BRAF mutations associate with increased miR-335 expression and inversely correlate with GJB5 expression. In clinical samples, GJB5 underexpression is also associated with patient overall worse survival, especially at early stages. Conclusion We identified a significant association between metastases / BRAF mutation and low GJB5 expression in melanoma. Our results identify a novel mechanism of Gap-junctional protein regulation, suggesting a prognostic role for GJB5 in cutaneous melanoma.
- Open Access
- 30 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (7) , 3567
Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors
Cutaneous squamous cell carcinomas (cSCCs) account for about 20% of keratinocyte carcinomas, the most common cancer in the UK. Therapeutic options for cSCC patients who develop metastasis are limited and a better understanding of the biochemical pathways involved in cSCC development/progression is crucial to identify novel therapeutic targets. Evidence indicates that the phosphoinositide 3-kinases (PI3Ks)/Akt pathway plays an important role, in particular in advanced cSCC. Questions remain of whether all four PI3K isoforms able to activate Akt are involved and whether selective inhibition of specific isoform(s) might represent a more targeted strategy. Here we determined the sensitivity of four patient-derived cSCC cell lines to isoform-specific PI3K inhibitors to start investigating their potential therapeutic value in cSCC. Parallel experiments were performed in immortalized keratinocyte cell lines. We observed that pan PI3Ks inhibition reduced the growth/viability of all tested cell lines, confirming the crucial role of this pathway. Selective inhibition of the PI3K isoform p110α reduced growth/viability of keratinocytes and of two cSCC cell lines while affecting the other two only slightly. Importantly, p110α inhibition reduced Akt phosphorylation in all cSCC cell lines. These data indicate that growth and viability of the investigated cSCC cells display differential sensitivity to isoform-specific PI3K inhibitors.
- 30 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (7) , 3567
Open AccessGrowth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors
Cutaneous squamous cell carcinomas (cSCCs) account for about 20% of keratinocyte carcinomas, the most common cancer in the UK. Therapeutic options for cSCC patients who develop metastasis are limited and a better understanding of the biochemical pathways involved in cSCC development/progression is crucial to identify novel therapeutic targets. Evidence indicates that the phosphoinositide 3-kinases (PI3Ks)/Akt pathway plays an important role, in particular in advanced cSCC. Questions remain of whether all four PI3K isoforms able to activate Akt are involved and whether selective inhibition of specific isoform(s) might represent a more targeted strategy. Here we determined the sensitivity of four patient-derived cSCC cell lines to isoform-specific PI3K inhibitors to start investigating their potential therapeutic value in cSCC. Parallel experiments were performed in immortalized keratinocyte cell lines. We observed that pan PI3Ks inhibition reduced the growth/viability of all tested cell lines, confirming the crucial role of this pathway. Selective inhibition of the PI3K isoform p110α reduced growth/viability of keratinocytes and of two cSCC cell lines while affecting the other two only slightly. Importantly, p110α inhibition reduced Akt phosphorylation in all cSCC cell lines. These data indicate that growth and viability of the investigated cSCC cells display differential sensitivity to isoform-specific PI3K inhibitors.
- 15 June 2020
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (12) , 2676-2688
Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma
Targeting the MAPK pathway by combined inhibition of BRAF and MEK has increased overall survival in advanced BRAF-mutant melanoma in both therapeutic and adjuvant clinical settings. However, a significant proportion of tumors develop acquired resistance, leading to treatment failure. We have previously shown p63 to be an important inhibitor of p53-induced apoptosis in melanoma following genotoxic drug exposure. Here, we investigated the role of p63 in acquired resistance to MAPK inhibition and show that p63 isoforms are upregulated in melanoma cell lines chronically exposed to BRAF and MEK inhibition, with consequent increased resistance to apoptosis. This p63 upregulation was the result of its reduced degradation by the E3 ubiquitin ligase FBXW7. FBXW7 was itself regulated by MDM2, and in therapy-resistant melanoma cell lines, nuclear accumulation of MDM2 caused downregulation of FBXW7 and consequent upregulation of p63. Consistent with this, both FBXW7-inactivating mutations and MDM2 upregulation were found in melanoma clinical samples. Treatment of MAPK inhibitor–resistant melanoma cells with MDM2 inhibitor Nutlin-3A restored FBXW7 expression and p63 degradation in a dose-dependent manner and sensitized these cells to apoptosis. Collectively, these data provide a compelling rationale for future investigation of Nutlin-3A as an approach to abrogate acquired resistance of melanoma to MAPK inhibitor targeted therapy. Significance: Upregulation of p63, an unreported mechanism of MAPK inhibitor resistance in melanoma, can be abrogated by treatment with the MDM2 inhibitor Nutlin-3A, which may serve as a strategy to overcome resistance.
- 15 June 2020
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (12) , 2676-2688
Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma
Targeting the MAPK pathway by combined inhibition of BRAF and MEK has increased overall survival in advanced BRAF-mutant melanoma in both therapeutic and adjuvant clinical settings. However, a significant proportion of tumors develop acquired resistance, leading to treatment failure. We have previously shown p63 to be an important inhibitor of p53-induced apoptosis in melanoma following genotoxic drug exposure. Here, we investigated the role of p63 in acquired resistance to MAPK inhibition and show that p63 isoforms are upregulated in melanoma cell lines chronically exposed to BRAF and MEK inhibition, with consequent increased resistance to apoptosis. This p63 upregulation was the result of its reduced degradation by the E3 ubiquitin ligase FBXW7. FBXW7 was itself regulated by MDM2, and in therapy-resistant melanoma cell lines, nuclear accumulation of MDM2 caused downregulation of FBXW7 and consequent upregulation of p63. Consistent with this, both FBXW7-inactivating mutations and MDM2 upregulation were found in melanoma clinical samples. Treatment of MAPK inhibitor–resistant melanoma cells with MDM2 inhibitor Nutlin-3A restored FBXW7 expression and p63 degradation in a dose-dependent manner and sensitized these cells to apoptosis. Collectively, these data provide a compelling rationale for future investigation of Nutlin-3A as an approach to abrogate acquired resistance of melanoma to MAPK inhibitor targeted therapy. Significance: Upregulation of p63, an unreported mechanism of MAPK inhibitor resistance in melanoma, can be abrogated by treatment with the MDM2 inhibitor Nutlin-3A, which may serve as a strategy to overcome resistance.